Pharmacodynamics Study Guide

📖 Core Concepts Pharmacodynamics (PD): How drugs affect the body (biochemical & physiologic effects). Pharmacokinetics (PK): How the body affects the drug (ADME). Dose‑Response Relationship: Describes how increasing drug concentration changes the magnitude of effect; key for potency and efficacy. Drug‑Receptor Binding: Governed by the law of mass action; equilibrium expressed by the dissociation constant \(Kd\). Occupancy: Fraction of receptors bound, \(\displaystyle \text{Occupancy}= \frac{[L]}{[L]+Kd}\). Therapeutic Window: Concentration range between minimal effective dose and dose causing unacceptable toxicity. Receptor Reserve: Excess receptors that let a maximal response be reached before full occupancy. Functional Selectivity (Biased Agonism): A ligand preferentially triggers specific downstream pathways, leading to distinct effects. --- 📌 Must Remember \(Kd\) definition: \(Kd = \frac{[L][R]}{[LR]}\). Lower \(Kd\) → higher affinity. 50 % occupancy occurs when \([L] = Kd\). Potency vs. Efficacy: Potency = concentration needed for a given effect (left‑shift curve). Efficacy = maximal possible effect. Agonist Types: Full agonist – maximal response. Partial agonist – sub‑maximal even at full occupancy. Inverse agonist – produces opposite effect of the endogenous ligand. Antagonist Types: Competitive – reversible, shifts curve right, can be overcome with more agonist. Non‑competitive/Uncompetitive – reduces maximal response, not overcome by more agonist. Therapeutic Window: Narrow → requires plasma level monitoring (e.g., cardiac glycosides). Tolerance: Repeated exposure → decreased responsiveness → higher dose needed. Adverse Reaction Types: Type A (intrinsic): Dose‑dependent, predictable. Type B (idiosyncratic): Not dose‑dependent, often immune‑mediated. --- 🔄 Key Processes Ligand‑Receptor Binding Equilibrium \(L + R \rightleftharpoons LR\) Association rate \(k{\text{on}}[L][R]\); dissociation rate \(k{\text{off}}[LR]\). At equilibrium: \(Kd = k{\text{off}}/k{\text{on}}\). Generating a Dose‑Response Curve Vary dose → measure effect → plot % response vs. log[Drug]. Identify EC₅₀ (concentration for 50 % of maximal effect). Determining Therapeutic Window Find Minimum Effective Concentration (MEC) and Minimum Toxic Concentration (MTC). Therapeutic Index = \( \frac{MTC}{MEC}\). Developing Tolerance Repeated exposure → receptor down‑regulation, increased metabolism, or functional desensitization. Assessing Functional Selectivity Test ligand’s ability to activate multiple downstream pathways (e.g., G‑protein vs. β‑arrestin). --- 🔍 Key Comparisons Agonist vs. Antagonist Agonist → activates receptor → response. Antagonist → blocks receptor → no response (or opposite if inverse). Competitive vs. Non‑competitive Antagonist Competitive → reversible, shifts dose‑response right, same Emax. Non‑competitive → reduces Emax, cannot be overcome by higher agonist. Full vs. Partial Agonist Full → can elicit 100 % of possible response. Partial → capped below 100 % even at full occupancy. Type A vs. Type B Adverse Reactions Type A → predictable, dose‑related (e.g., hypotension from ACE inhibitors). Type B → unpredictable, not dose‑related (e.g., penicillin anaphylaxis). Narrow vs. Wide Therapeutic Window Narrow → small margin of safety; requires monitoring (e.g., digoxin). Wide → larger safety margin; less frequent monitoring (e.g., ibuprofen). --- ⚠️ Common Misunderstandings “Higher potency = stronger drug.” Potency only reflects needed concentration, not maximal effect. Assuming all antagonists are competitive. Many clinically important antagonists are non‑competitive or irreversible. Equating receptor occupancy with effect. Due to receptor reserve, 50 % occupancy can produce near‑maximal response. Thinking tolerance only involves receptor numbers. Metabolic induction and downstream signaling changes also contribute. Confusing therapeutic index with therapeutic window. Index is a ratio (MTC/MEC); window is the actual concentration range. --- 🧠 Mental Models / Intuition “Lock‑and‑Key vs. Volume‑Control”: Lock‑and‑Key → simple occupancy (more keys = more doors opened). Volume‑Control → receptor reserve/amplification lets a few keys (low occupancy) turn the volume up to full. “Sliding Scale”: Visualize dose‑response curves as sliding scales; a left shift = higher potency, a lower plateau = lower efficacy. “Therapeutic Tightrope”: Narrow window drugs require you to stay balanced (monitor levels) or you fall into toxicity. --- 🚩 Exceptions & Edge Cases Irreversible inhibitors (e.g., aspirin) do not follow simple reversible binding equations; effect depends on enzyme turnover. Allosteric modulators can change both affinity (Kd) and efficacy without occupying the orthosteric site. Biased agonists may produce therapeutic effect through one pathway while avoiding side effects mediated by another. High‑affinity, low‑efficacy partial agonists can act as functional antagonists in the presence of a full agonist (e.g., pindolol). --- 📍 When to Use Which Choosing an agonist vs. partial agonist: Use partial agonist when you need a ceiling effect to avoid overstimulation (e.g., buprenorphine for opioid dependence). Competitive vs. non‑competitive antagonism: Prefer competitive antagonists when dose titration is possible; use non‑competitive when you need to blunt maximal response regardless of agonist level (e.g., NMDA antagonists). Allosteric modulator vs. orthosteric drug: Opt for allosteric agents when you want to fine‑tune receptor activity without fully activating or blocking the receptor. Monitoring strategy: Use plasma level monitoring for drugs with narrow therapeutic windows; rely on clinical signs for wide‑window agents. --- 👀 Patterns to Recognize Left‑shifted dose‑response → higher potency or increased receptor affinity. Lower maximal response with same EC₅₀ → non‑competitive antagonism or reduced efficacy. Steep slope → high cooperativity or strong signal amplification. Repeated dosing → tolerance often shows a rightward shift of the curve over time. Adverse reaction type clues: Sudden, unpredictable reactions → think Type B; dose‑related predictable effects → Type A. --- 🗂️ Exam Traps “More receptors = more effect.” Trap: Ignoring receptor reserve; even few occupied receptors can give maximal response. Confusing \(Kd\) with EC₅₀. Trap: \(Kd\) reflects binding affinity; EC₅₀ reflects functional potency and is influenced by efficacy and signal amplification. Assuming all irreversible inhibitors are “stronger.” Trap: Their duration depends on enzyme turnover, not just binding strength. Mix‑up between therapeutic index and therapeutic window. Trap: Index is a ratio; window is an actual concentration range clinicians manage. Attributing tolerance solely to receptor down‑regulation. Trap: Metabolic enzyme induction can also cause tolerance. ---